imaging
Meilleur Technologies' Amyloid PET Imaging Tool to Be Used in CLARiTI Study
The National Institute of Aging's Alzheimer's Disease Research Centers will recruit 2,000 participants and use NAV-4694 to study amyloid pathology in Alzheimer's and related disorders.
GE Healthcare Licenses Sofie Biosciences' FAP-Targeting Diagnostic Radiopharmaceuticals
GE gained worldwide rights to develop and commercialize Sofie's gallium 68-labeled PET imaging agent and ex-US rights to its fluorine 18-labeled PET imaging agent.
Blue Earth Diagnostics' PSMA-Directed PET Imaging Agent Gets CMS Pass-Through Payment Status
The US Centers for Medicare & Medicaid Services has agreed to reimburse hospital outpatient centers for Posluma as it collects additional information on cost.
Perspective Therapeutics Treats First Metastatic Melanoma Patient in Radiopharmaceutical Trial
The firm is evaluating its targeted alpha therapy 212Pb-VMT01 in patients whose tumors express MC1R, as determined by a PET imaging agent.
Telix Pharmaceuticals Treats First Glioblastoma Patient in Phase I Radiopharmaceutical Trial
Telix is evaluating TLX101 plus chemo and radiation in newly diagnosed glioblastoma patients whose cancers express LAT-1 based on PET imaging with TLX101-CDx.